Browse studies

Find your next paid study

5 recruiting studies matching your filters

Alert-Based Computerized Decision Support for Identification and Management of Patients With Familial Hypercholesterolemia (FH-ALERT Trial)

The goal of this clinical trial is to learn if a computer alert can aid clinicians in identifying patients with a genetic type of high cholesterol, called Fami…

Familial Hypercholesterolaemia

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT06743659

Phase 1

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are ref…

CardiovascularMetabolic DiseaseDyslipidemias+7 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT07491172

Phase 3

A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients

This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small…

Hypercholesterolaemia

Estimated

~$10 – $7,500

AstraZenecaNCT07619131

Observational

Arizona CEAL: Linking Social Care With Healthcare Systems to Address SDOH

The goal of the Arizona Community Engagement Alliance (AZ-CEAL) will be to combine social care with healthcare programs. The study will be connecting selected …

Social Determinants of Health (SDOH)HypertensionDiabetes Mellitus+1 more

Estimated

~$10 – $7,500

Sairam ParthasarathyNCT07799961

Phase 2

A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia

This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of Q…

Hypercholesterolaemia

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07610278